Abstract 807P
Background
Ovarian cancer (OC) is the most lethal gynecologic tumor and is characterized by a widespread metastasis in abdominal cavity. Accurate preoperative evaluation is important for the specification of surgical procedures and prediction of surgical outcomes.Currently, a variety of imaging techniques can be used for preoperative evaluation of ovarian cancer such as the Computed Tomography (CT) Suidan score. However, the Magnetic resonance imaging (MRI) based preoperative evaluation was not fully explored. Here, our study explores the feasibility of MRI as a preoperative assessment in OC patients.
Methods
This is a prospective, non-randomized, single-center trial of 134 epithelial ovarian cancer (EOC) patients treated with surgical cytoreduction between 2018 and 2022. All patients underwent preoperative MRI scan. The imaging score consists of lesion size scores in 33 areas of the abdominal cavity.
Results
Complete cytoreduction (CC) was achieved in 81 (60.4%) of 134 patients. CC patients with a median MRI score of 10(4 - 44) and the median MRI score of patients who were incompletely cytoreduced (IC) was 15(5 - 48). By comparing imaging scores with those seen in surgery, we found that MRI evaluation is in good agreement with intraoperative observation. However, for areas such as the small bowel mesentery, the MRI score is lower than the intraoperative score, while for lymph node metastases the MRI score is higher than the intraoperative score. Through multi-factor analysis, we have screened clinical and imaging criteria related to IC including CA125 level, prognostic nutritional index (PNI), diaphragmatic surface of spleen lesion, gallbladder fossa lesion and small bowel mesentery lesion. Based on these criteria, we have constructed preoperative imaging scores and the ‘predictive score’ was assigned to each criterion based on its multivariate OR.
Conclusions
Our research explores the feasibility of incorporating tumor load into MRI based preoperative assessment for OC patients. Also, we identified 5 criteria associated with IC, and developed a predictive model which may be helpful in treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11